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Opinion statement
Allergic diseases are among the most common health issues worldwide. Specific
immunotherapy has remained the only disease-modifying treatment, but it is
not effective in all patients and may cause side effects. Over the last 25 years,
allergen molecules from most prevalent allergen sources have been isolated and
produced as recombinant proteins. Not only are these molecules useful in im-
proved allergy diagnosis, but they also have the potential to revolutionize the
treatment of allergic disease by means of immunotherapy. Panels of unmodified
recombinant allergens have already been shown to effectively replace natural al-
lergen extracts in therapy. Through genetic engineering, several molecules have
been designed with modified immunological properties. Hypoallergens have been
produced that have reduced IgE binding capacity but retained T cell reactivity and T cell pep-
tides which stimulate allergen-specific T cells, and these have already been investigated in
clinical trials. New vaccines have been recently created with both reduced IgE and T cell reac-
tivity but retained ability to induce protective allergen-specific IgG antibodies. The latter ap-
proach works by fusing per se non-IgE reactive peptides derived from IgE binding sites of the
allergens to a virus protein, which acts as a carrier and provides the T-cell help necessary for
immune stimulation and protective antibody production. In this review, we will highlight the
different novel approaches for immunotherapy and will report on prior and ongoing clinical
studies.
Introduction
In industrialized societies, allergic diseases are
among the most prevalent health issues, affecting
up to 25 % of the population [1]. There are two
main facets of the allergic response. The first is
the immediate-type responses triggered by cross-
linking of IgE antibodies on the surface of mast
cells and basophil granulocytes by the allergen,
followed by the release of inflammatory mediators,
cytokines, and proteases, thus inducing symptoms
within minutes of allergen contact. The second facet
of the allergic response is caused by the activation
of allergen-specific T cells, which produce pro-in-
flammatory cytokines and can lead to late-phase re-
actions and the more chronic forms of allergic
inflammation. Although this phase of the allergic
reaction can be significantly enhanced via IgE-facil-
itated allergen presentation by B cells [2], it can al-
so occur without the presence of IgE epitopes. The
latter has been shown by the induction of late asth-
matic reaction after injection of short allergen pep-
tides, which represented T cell epitopes but were
devoid of IgE binding sites [3–5].
Although allergic symptoms can often be effec-
tively suppressed using various drugs, only allergen
immunotherapy is able to impact on the underly-
ing immune mechanism and leads to long-lasting
change in the course of allergic disease [6]. Conven-
tional immunotherapy involves the repeated subcu-
taneous or sublingual administration of crude
natural extracts of the allergen source over a period
of two to three years or longer [7]. This treatment
has been shown to improve symptoms and de-
crease the risk of progression of the disease to more
severe forms (e.g., from rhinitis to asthma) [8, 9].
Allergen immunotherapy is effective for certain al-
lergen sources (e.g., seasonal allergens, hymenop-
tera venom), while results are less convincing for
others (e.g., mould spores, animal dander). Further-
more, treatment is time-consuming and somewhat
arduous, with treatment outcomes that are unpre-
dictable and vary from patient to patient and the
potential for side effects.
Ideally, allergen extracts should contain stable and
sufficient amounts of all relevant allergenic proteins. In
reality, however, this is often not the case, as the content
and quality of extracts is dependent on the source mate-
rial, which shows natural variations, thus causing vari-
ability [10–13, 14•]. This issue remained unresolved
until recombinant allergens became available [15, 16].
Over the last 25 years, amultitude of allergens have been
produced as recombinant proteins and have beenmetic-
ulously characterized. The grouping of homologous al-
lergens into allergen families allowed the change from
a taxonomy-based to a protein family-based classifica-
tion [17–19], which elucidated the causes of cross-reac-
tivity between taxonomically unrelated allergen sources
[20, 21]. Furthermore, it was possible to distinguish be-
tween clinically relevant allergen molecules and others
that were capable of binding IgE antibodies but are of
minor clinical importance for allergic patients. This is
the basis for the formulation of recombinant allergy vac-
cines that containonlymolecules of clinical relevance for
allergic patients [22].
Allergen components can be used in various ways
to improve treatment options for allergic patients.
Panels of unmodified recombinant or purified natu-
ral allergens, which emulate the allergen contents of
natural extracts – albeit in a highly standardized
manner and lacking non-allergenic extract compo-
nents – have already been used in therapy for grass
pollen- and birch pollen-allergic patients [23, 24]. A
further developmental step was the use of recombi-
nant technology to produce allergen derivatives, in-
cluding hypoallergenic allergen derivatives [25–27],
allergen hybrid proteins [28–30], and T cell peptides
[31, 32], with the goal of improving the reliability
and safety of vaccines and decreasing the number
of injections.
In this article, we will describe the different strate-
gies for the use of recombinant allergens and allergen
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derivatives for the treatment of allergic patients and
provide an overview of studies that have been con-
ducted or are currently ongoing. Additionally, we will
discuss the monitoring of immunotherapy outcomes
using new, test methods [33•], and discuss how the
ever-growing availability of well-characterized allergen
components may lead to personalized treatment of
allergic patients. The last chapter of this article is
devoted to the use of modified allergen compo-
nents for the possible prophylactic treatment in in-
dividuals with a high risk of developing allergic
disease.
Treatment forms based on recombinant
allergens and peptides
Vaccines based on selected unmodified recombinant allergens
Several disadvantages of extract-based SIT (i.e., variable composition and
allergen content [10–13, 14•], lack of allergen components [10, 11], con-
tamination with other allergen sources [34], or bacterial components [35,
36]) can be overcome by using selected panels of unmodified recombinant
or purified natural allergens for SIT. Evidence that this approach is effective
has already been produced in two separate published clinical trials. In the
first immunotherapy trial, grass pollen-allergic patients were treated with an
equimolar mixture of the five major timothy grass pollen allergens (rPhl p 1,
2, 5a, 5b, and 6). A clinical benefit was associated with modification of the
specific immune response with promotion of IgG and reduction of IgE an-
tibodies [23]. In another trial, treatment of birch pollen-allergic patients with
the recombinant major birch pollen allergen rBet v 1 was compared to
treatment with purified natural Bet v 1 standard extract therapy or placebo.
This multicenter study of 134 patients demonstrated that a single allergen
was as effective as the purified natural allergen, which contained several
isoforms, and the whole birch pollen extract [24]. Recombinant Bet v 1 has
also been investigated for sublingual use [37, 38].
Because unmodified recombinant allergens have immunological features
equal to their natural counterparts, they bear the risk of inducing adverse
allergic events as a consequence of IgE or T cell reactivity. To overcome this
problem, several different strategies have been developed to improve SIT
vaccines.
Vaccines with reduced IgE reactivity and retained T cell reactivity
Due to the fact that many IgE epitopes are conformational, IgE binding to
allergens is often dependent on their correctly folded tertiary structure.
One way to change or destroy conformational IgE epitopes is by frag-
mentation or oligomerisation of allergens. In a study performed in 1999–
2000, a mixture of two recombinant Bet v 1 fragments and a recombinant
Bet v 1 trimer were compared with placebo for subcutaneous SIT of birch
pollen-allergic patients. Patients from both treatment groups developed
protective IgG antibody responses against Bet v 1-related pollen and food
allergens, and had a reduced boost of IgE memory responses during the
birch pollen season. A reduction of cutaneous sensitivity to Bet v 1 was also
observed [4, 25, 39, 40].
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Another way to modify the structure of recombinant allergens is the
production of folding variants by reduction and alkylation, as was dem-
onstrated for Bet v 1 [41, 42]. In a dose-finding study using the resulting
vaccine, individuals treated with the rBet v 1 folding variant exhibited
lower symptom medication scores than the extract-treated control group
[43].
Further attempts to reduce the IgE binding capacity of allergens have been
made by the introduction of point mutations by site-directed mutagenesis of
cysteines to disrupt disulfide bonds, the deletion of parts of the sequences,
and the fusion of allergen variants. Thus far, these methods have not been
used in patient therapy (reviewed in [15]).
Vaccines based on T cell peptides
Synthetic T cell peptides may represent another alternative to recombi-
nant allergens, as they encompass T cell epitopes while lacking the
conformational IgE epitopes of the native allergen. When this approach
was first investigated in cat-allergic patients, injection of short T cell
peptides of Fel d 1, the major cat allergen, were associated with late-
onset symptoms of rhinitis, asthma, and pruritus [44]. These issues were
later largely overcome by the use of slightly longer peptides. However,
the T cell-mediated side effects demonstrated that T cell-mediated late-
phase reactions can occur in the absence of IgE epitopes. Current studies
with immunodominant T cell epitopes showing promiscuous MHC
binding are being conducted to define the optimal dose and dose in-
terval [45•, 46].
A similar approach was used to vaccinate against the bee venom allergen
phospholipase A2 (PLA2), which induced PLA2-specific IgG4, T cell hypo-
responsiveness, Th1 cytokine deviation, and PLA2 peptide-specific IL-10
production, and which was well-tolerated by patients [47, 48]. The T cell
peptide approach was further explored in a recent study using a combination
of three long Bet v 1-derived peptides [49]. Due to the fact that rather long
peptides were used and allergen-specific IgG responses were induced, this
was not a purely T cell peptide-based approach, but was similar to an earlier
study where recombinant Bet v 1 fragments were used to induce allergen-
specific IgG [25, 50].
Vaccines based on allergen derivatives with reduced IgE and T cell reactivity
A recently developed approach for a safe allergy vaccine is based on the
hapten-carrier principle, where per se non-IgE-reactive allergen-derived
peptides are covalently coupled to carrier proteins, such as viral proteins,
in order to induce allergen-specific IgG antibodies with carrier-based T
cell help [51]. Peptides, approximately 25–40 amino acids in length,
derived from the IgE binding sites of allergens are derived from the IgE
binding sites of allergens are selected and fused with a non-allergenic
carrier protein that provides T cell help for the induction of carrier-spe-
cific and allergen-specific IgG.
This vaccine design was evaluated with peptides derived from the ma-
jor allergens from timothy grass pollen (Phl p 1 and Phl p 5) [52, 53•],
birch pollen (Bet v 1) [54], olive pollen (Ole e 1) [55], and the Alternaria
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alternata mould [56] by chemical coupling to keyhole limpet hemocyanin
as carrier. Vaccination of mice and rabbits induced specific IgG antibodies
that were able to inhibit the binding of IgE of allergic patients to the
natural allergens.
As chemical conjugation may deliver end products of varying compo-
sition, it is not ideally suited for vaccine production under GMP con-
ditions, it is not ideally suited for vaccine production. Therefore, defined
recombinant fusion proteins consisting of the carrier protein and various
numbers and combinations of the allergen-derived peptides were devel-
oped [57]. Examples of this approach are vaccines consisting of the
rhinovirus-derived coat protein VP1 fused to Phl p 1-derived peptides
[58] or vaccines based on the PreS domain of hepatitis B virus fused to
cat-derived and birch pollen-derived peptides [59••, 60]. With the use of
such technology, protective immunity against allergens and viral infec-
tions may be induced, thus providing the possibility to create combi-
nation vaccines for therapy and prophylaxis of allergy and infectious
diseases [57].
Phase I and IIa clinical studies (NCT01350635, NCT01445002) were re-
cently concluded on the BM32 vaccine, which consists of PreS fused to non-
allergenic peptides from the 4 major timothy grass pollen allergens Phl p 1,
2, 5, and 6. A double-blind placebo-controlled multicenter phase IIb study
(NCT01538979) is currently underway.
Another approach that was recently described involves the introduc-
tion of random mutations into allergen-encoding DNA and the expres-
sion of the recombinant mutants in phage libraries. IgE antibodies of
allergic patients are used for phage enrichment to generate allergy vac-
cines with maintained structure but altered allergenic activity, as evalu-
ated for Fel d 1. The resulting mutants induced blocking antibodies in
immunized mice [61]. Table 1 provides an overview of the features of
various allergen derivatives developed for immunotherapy. References with
an asterisk refer to treatment forms which have been or currently are
tested in SIT trials.
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- - + - - [52, 53•, 54–56, 58,
59••, 60, 74, 75]
*Indicates references which refer to clinical studies
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New routes for the application of vaccines based on recombinant allergens
Although subcutaneous and immunotherapy are currently the most
frequently used routes of allergen delivery, other approaches such as
oral, nasal, bronchial, epicutaneous, intraepithelial, intralymphatic, and
rectal IT have been explored. Oral immunotherapy [76] has been pro-
posed for desensitization in food allergy with the aim of inducing
tolerance [77].
In this context, one new approach is edible transgenic rice containing stor-
age protein bodies that are resistant to proteolytic degradation and may be
suitable for bioencapsulation of allergens [64–66, 78]. In order to increase
the safety of edible vaccines, hypoallergenic variants [67] and a Bet v 1
tolerogen generated by DNA shuffling [68] were introduced into transgenic
rice. A possibility to improve sublingual or mucosal delivery of allergens is to
combine recombinant allergens with mucoadhesive substances. This ap-
proach has thus far been evaluated in a murine model of chronic birch
pollen respiratory allergy with rBet v 1 formulated in amylopectin-based
microparticles [62].
Epicutaneous delivery of immunotherapy is another route currently under
investigation for immunotherapy [79], and this involves either the use of
patches [80, 81] or a specially developed delivery system [82] of allergen
application. Both studies have provided evidence that epicutaneous immu-
notherapy may be safe and effective.
Transcutaneous immunotherapy via laser-generated micropores and co-
application of CpG has been described to increase the safety of the therapy
by abrogating the Th2 polarizing potential of skin immunization [83].
Another possibility for allergy vaccination is intralymphatic immunother-
apy (ILIT). A study with a limited number of patients showed that ILIT with
grass pollen or birch pollen extracts reduced nasal allergic symptoms without
causing safety problems [84]. Using the same delivery method, a modular
antigen transporter vaccine based on recombinant Fel d 1, the major cat al-
lergen, was fused to the HIV TAT-derived translocation peptide and part of
the human invariant chain in order to target the construct to the MHC class II
pathway [69•]. In a first-in-human clinical study, ILIT with MAT-Fel d 1
stimulated regulatory T cell responses and increased cat dander-specific IgG
levels [69•].
For cockroach allergy, a novel intranasal liposome-adjuvanted vaccine
containing Per a 9 (Periplaneta americana arginine kinase) was tested in
mice and found to attenuate allergic airway inflammation upon allergen re-
exposure better than liposome-entrapped P. americana crude extract [85].
An approach based on rectal application used heat/phenol-inactivated E.
coli-encapsulated, recombinant modified major peanut allergens and was
tested in a phase I clinical trial. However, rectal administration resulted in
frequent adverse reactions, including severe allergic reactions in 20 % of
study participants [70].
Companion diagnosis and monitoring of the success of SIT
Several mechanisms induced by the therapeutic injection of allergen extracts,
such as the induction of blocking antibodies, have been suggested to mediate
96 Specific Immunotherapy (L Cox, Section Editor)
the beneficial effect of specific immunotherapy (SIT). Strong experimental
evidence has been provided that these antibodies – mostly IgG – prevent the
allergen-induced activation of mast cells and basophils by competing with
IgE for the binding to allergen molecules [reviewed in 15, 86, 87].
Despite improved efficacy of extract-based immunotherapy, many pa-
tients still do not exhibit significant clinical improvement after as much as
three years of therapy. In defining the reasons for the failure of SIT, several
factors must be considered. First, in the case of complex allergen sources like
timothy grass pollen or house dust mite that contain multiple allergens that
can trigger symptoms, sensitization profiles may vary significantly between
allergic individuals [88]. Extract-based measurement of IgG after immuno-
therapy does not provide information that the vaccination has induced IgG
to all allergen molecules that the patient is sensitized to, as only total reac-
tivity to an allergen source is measured when extracts are used. In addition,
since extract-based tests contain both allergens and non-allergenic compo-
nents, the serological test may also be positive in the case of exclusive pro-
duction of therapeutically irrelevant IgG to non-allergenic components.
These diagnostic constraints have been partially overcome with the avail-
ability of serological tests comprising purified allergen molecules [89], as
only antibodies specific to defined allergens are detected by these tests.
Generally, two types of tests are available: tests for antibodies specific to
single allergen molecules, and test systems using microarray technology that
measure Ig reactivities to more than 100 components in a single step [90,
91••, 92].
In tests for reactivity to single allergen molecules, a relatively large
amount of the purified allergen molecule is used for Ig detection when
compared to average titers of allergen-specific antibodies in the serum.
Hence, all antibodies in the sample that recognize the respective allergen –
IgE as well as IgG – can be bound and detected. In this way, the test allows
quantitative measurement of the respective antibody species, which may be
relevant, for example, in the quantification of an IgE-boost by vaccination.
However, if the IgG-response to SIT has to be measured, results of this test
may be misleading because they do not distinguish blocking from non-
blocking IgG. Even if only therapeutically irrelevant non-blocking IgG were
induced, the test would yield a positive result. Furthermore, when assessing
the immunological efficacy of SIT, it is important to determine that a vac-
cination produced a protective IgG “shield” covering all relevant allergens the
patient is sensitized to. In the case of complex allergen sources, many single
tests are required to obtain a comprehensive analysis of the patient’s immune
response.
Allergen microarrays [90] typically comprise a large number of allergen
molecules, usually more than 100 components, yielding the patient’s Ig-re-
activity profile in a single step. With this technology, it is possible to assess
whether a vaccination with an allergen extract successfully induced IgG to all
relevant allergen components, or whether, due to the lack of a particular
allergen in the extract, for example, IgG-reactivity to the allergen could not be
achieved, which would thus explain therapeutic failure. Likewise, the
blocking ability of allergen-specific IgG can be determined by microarray
[91••]. In this instance, because only small amounts of protein are coupled
to the surface (in the range of 50–200 fg per spot, which is approximately
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10,000,000 times less than in tests comprising single allergens), this results
in the restriction of the number of epitopes available for antibody binding. If
a sample contains both IgE and IgG that bind to the same allergen but to
different epitopes, both isotypes can bind independently without affecting
the binding of the other isotype. By contrast, if IgE and IgG bind to the same
epitopes or to epitopes in close proximity on the allergen surface, competi-
tion will mutually decrease the detected IgE and IgG levels. Therefore, a de-
creased IgE signal detected by microarray after specific immunotherapy as
compared to the level before SIT may indicate that blocking IgG antibodies
have been induced.
In this context, allergen microarrays facilitate analysis of the immune re-
sponse of a patient treated by specific immunotherapy, enabling the physi-
cian to identify “holes” in the protective IgG-shield and to distinguish
clinically relevant from insufficient IgG responses upon vaccination.
In addition to these clinically well-established serological tests, several
methods are under investigation that may help assess and predict the
success of SIT [93] or distinguish clinically beneficial from adverse im-
mune responses to SIT [94]. Assays like the basophil activation test, for
example, could serve as surrogates for in vivo tests [95], while the IgE-
FAB assay allows the determination the blocking effect of SIT on IgE-
facilitated allergen presentation [96].
Personalized allergy treatment based on allergen components:
closer than we think?
The goal of personalized medicine is to tailor and/or optimize treatment for
each individual patient exactly to his or her personal situation. The topic has
been widely discussed in the context of genetics, and largely advocates the
use of new technologies to customize medicine for the benefit of patients. It
may be considered ironic that customized medicine prescribed by medical
doctors for individual patients and manually compounded by pharmacists
was far more common before production and packaging of medicine became
widely industrialized. Along the same lines, conventional allergen immu-
notherapy could also be regarded as a classic form of personalized medicine.
In Europe, therapeutic allergen extract preparations were and still are largely
ordered from pharmaceutical companies that produce, package, and label
them for individual patients.
Similar to other pre-packaged medicines, few immunotherapy prepara-
tions have received full regulatory approval in the EU. Although the regula-
tory situation varies among different countries, drug products customized for
individual patients generally do not have the same stringent approval re-
quirements as other drugs [97]. On this basis, it was possible to make
available a multitude of allergen extracts from a wide variety of allergen
sources for the treatment of allergic patients, and the efficacy of many of
these extracts has never been proven in controlled clinical trials. However,
the widespread use of component-resolved diagnosis has revealed that most
patients are sensitized to only a small number of different proteins. It has
become clear that due to the high degree of cross-reactivity between allergen
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extracts from different sources, most allergic patients could be effectively
treated with a small number of well-selected allergen components. This
would have several advantages, including the avoidance of injecting allergens
against which patients have no IgE sensitization.
In contrast to allergen extracts, market authorization of vaccines based on al-
lergen components, recombinant allergens, allergen derivatives, and allergen
peptides is extremely stringent and closely regulated (European Medicines
Agency (EMA) guidelines published June 1, 2009: http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500003605.pdf ). At this time, allergen vaccines need to undergo tests for
market authorization in their final composition. This means that current regu-
lations represent a hurdle for obtaining market authorization for individual
components for use in different mixtures according to sensitization profiles of
patients. As clinical trials for immunotherapy preparations are extremely costly,
the current regulatory situation certainly slows the development of personalized
treatment for allergic patients based on individual sensitization patterns. One
way to speed up progress and improve the situation would be to allow market
authorization for combination vaccines based on studies demonstrating com-
mon immunological mechanisms for individual allergen components, as is
common practice in the field of vaccines for infectious diseases.
In summary, therefore, although it is already technically possible to treat
each individual allergic patient precisely according to his or her sensitization
profile, this practice is currently held back by the prevailing market authoriza-
tion guidelines. Clinical studies investigating common mechanisms of SIT for
different defined allergen components are urgently needed as the basis for new
guidelines to allow the development of personalized forms of SIT.
Outlook – prophylactic vaccination against allergies
Allergen-specific immunotherapy (SIT) is the only causative and disease-
modifying treatment for IgE-mediated allergies. However, SIT aims to change
an already established and misled immune response. The treatment does not
cure the disease or restore healthy immune response [86]. Because allergies
are a major health problem with high socioeconomic costs, it would be of
great interest to have a prophylactic form of treatment that can prevent the
development of IgE-mediated allergies, as has been standard for many years
in infectious disease (e.g., hepatitis B, tetanus, or poliomyelitis).
There is no reason to believe that a prophylactic vaccination against IgE-
mediated allergies is not possible, but it would have to fulfil certain re-
quirements. First, and most importantly, the vaccine must be safe. Current
SIT preparations are based on natural allergen extracts that can lead to an
increase of allergen-specific IgE in allergic patients, and which would there-
fore bear the risk of sensitizing non-allergic individuals when used as pro-
phylactic treatment [98]. It is possible that this issue could be overcome by
the use of suitable hypoallergenic vaccines.
In this context, recombinant allergen variants lacking the binding sites for
allergen-specific IgE would be good candidate molecules for prophylactic
vaccination due to the very low risk of sensitization to naturally occurring
allergens. The immunological effect of this form of treatment is thought to be
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the induction of protective blocking IgG antibodies, similar to prophylactic
vaccines against infectious diseases. These allergen-specific antibodies should
bind to the allergen and thus prevent stimulation of the immune system
(Fig. 1). Another possible approach is the application of allergen-specific T
cell peptides with the goal of inducing tolerance (Fig. 1) (reviewed in [99•]).
A second very important aspect for a prophylactic treatment is the selec-
tion of the best time window for vaccination. It is the nature of a prophy-
lactic treatment that it must be performed before the onset of the disease. The
investigation of the precise time when sensitization occurs is currently the
subject of large birth cohort studies [100] (http://medall-fp7.eu). It is
thought that individuals with an atopic genetic background are sensitized in
the first year(s) of life and become symptomatic when a certain threshold of
allergen-specific IgE is reached [101]. After this primary sensitization phase,
the IgE reactivity profile of allergic adults does not appear to undergo further
relevant change [102]. In this context, the scenarios for prophylactic allergy
vaccination under discussion include active vaccination or passive applica-
tion of blocking antibodies to the pregnant allergic mother and/ or early post-
Figure 1. Graphical depiction of the immunological effects of a prophylactic allergy vaccine on the sensitization phase (1) and
of therapeutic vaccination with hypoallergens and T cell peptides on immediate- (2) and late-phase (3) reactions.
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natal active vaccination of the offspring with the goal to induce tolerance. Sev-
eral animalmodels have demonstrated that the transmission of allergen-specific
protective IgG antibodies via the placenta or breast milk can prevent allergic
sensitization of the offspring [103, 104]. Furthermore, there is evidence that SIT
performed in pregnantmothersmay prevent allergic sensitization of the child as
SIT-induced blocking IgG are transferred through the placenta [105, 106].
The third aspect that must be considered is the selection of the most use-
ful panel of allergens. The definition of the most important allergens (i.e.,
those which most frequently cause allergic symptoms and those which cause
more severe forms of disease) is currently the subject of investigations de-
lineating sensitization profiles in different countries and populations [100,
107•] (http://medall-fp7.eu).
And, lastly, a target populationmust be defined of children who would ben-
efit most from a prophylactic treatment and should therefore be vaccinated.
Depending on the type of vaccine, it is conceivable that certain risk groups (e.g.,
those with an atopic family background) should be treated. An initial attempt to
further pursue this approach is currently undergoing clinical investigation. Two
hypoallergenic fragments of Bet v 1 that have previously been shown to induce
protective immune responses but no new IgE antibody responses in birch pol-
len-allergic patients are currently being used for vaccination of 20 non-allergic
adult individuals in a clinical phase I study (NCT01353924).
Summary
Over the last 25 years, most of the clinically relevant allergens from impor-
tant allergen sources have been isolated and produced as recombinant
molecules. Allergen components are already used in routine diagnostic set-
ting, but they can also improve the monitoring of patients undergoing al-
lergen immunotherapy. Panels of recombinant allergens may also replace
natural allergen extracts for the treatment of allergic patients. Genetic engi-
neering allows the production of innovative allergy vaccines designed to re-
duce side effects, enhance clinical efficacy, and increase treatment
convenience. Based on several clinical studies performed with recombinant al-
lergens, hypoallergens, and peptides, it is clear that such vaccines will greatly
improve SIT andmay beuseful for prophylaxis.However, further clinical studies
are needed for these new vaccines to become available for patients.
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